A Phase 1 interventional study of Bictegravir and Placebo in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 16 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-11-09.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to investigate the short-term antiviral potency of bictegravir at multiple doses in antiretroviral (ART) treatment-naive adult participants and participants who are ART-experienced but integrase strand transfer inhibitor (INSTI) naive.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bictegravir 5 mg (1 × 5 mg tablet) for 10 days
Drug: Bictegravir
Bictegravir 25 mg (1 × 25 mg tablet) for 10 days
Drug: Bictegravir
Bictegravir 50 mg (2 × 25 mg tablets) for 10 days
Drug: Bictegravir
Bictegravir 100 mg (1 × 100 mg tablet) for 10 days
Drug: Bictegravir
Placebo matched to bictegravir tablet for 10 days
Drug: Placebo
Bictegravir tablet(s) administered orally once daily
Placebo to match bictegravir administered orally once daily
Time-Weighted Average Change From Baseline up to Day 11 (DAVG11) in Plasma HIV-1 RNA
DAVG11 was defined as the time-weighted average between the first postbaseline value through the last available on-treatment (ie, the last dose date + 1) value up to Day 11 minus the baseline value in plasma HIV-1 RNA (log10 copies/mL). All HIV-1 RNA data up to Day 11 were used for this analysis. DAVG11 was calculated using the trapezoidal rule and the area-under-the-curve concept.
Time frame: Baseline up to Day 11
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)
Time frame: First dose date up to last dose date plus 30 days (Maximum: 40 days)
Percentage of Participants Who Experienced Graded Laboratory Abnormalities
A treatment-emergent graded laboratory abnormality was defined as an increase of at least 1 toxicity grade from predose assessment and occurring after the predose visit and on or before the date of the last dose of study drug plus 30 days. If the predose assessment was missing, then any abnormality of at least Grade 1 associated with the study drug was considered a treatment-emergent graded laboratory abnormality. The most severe graded abnormality from all tests was counted for each participant.
Time frame: First dose date up to last dose date plus 30 days (Maximum: 40 days)
Maximum Reduction From Baseline Through Day 17 in Plasma HIV-1 RNA
Maximum reduction from baseline was defined as the minimum of change from baseline in plasma HIV-1 RNA (i.e. smallest change in HIV-RNA from baseline).
Time frame: Baseline to Day 17
Viral Decay Slope in Plasma HIV-1 RNA
Viral Decay Slope = (log10 \[HIV-1 RNA on Day x\] - log10 \[HIV-1 RNA on Day 1\]) / (x-1), where x is the collection day of the last available on treatment HIV-1 RNA collected up to Day 7.
Time frame: Baseline up to Day 11
Percentage of Participants With HIV-1 RNA < 50 Copies/mL
Time frame: Day 17
Pharmacokinetic (PK) Parameter: Cmax of Bictegravir Following Single-Dose and Multiple-Dose Administration
Cmax is defined as the maximum concentration of drug.
Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 for single dose and Day 10 for multiple dose
PK Parameter: Tmax of Bictegravir Following Single-Dose and Multiple-Dose Administration
Tmax is defined as the time (observed time point) of Cmax.
Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 for single dose and Day 10 for multiple dose
PK Parameter: AUC0-24 of Bictegravir Following Single-Dose Administration
AUC0-24 is defined as the concentration of drug over time from time zero to time 24 hours.
Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1
PK Parameter: AUClast of Bictegravir Following Single-Dose Administration
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1
PK Parameter: AUCtau of Bictegravir Following Multiple-Dose Administration
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10
PK Parameter: t1/2 of Bictegravir Following Multiple-Dose Administration
t1/2 is defined as the estimate of the terminal elimination half-life of the drug.
Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10
PK Parameter: Ctau of Bictegravir Following Multiple-Dose Administration
Ctau is defined as the observed drug concentration at the end of the dosing interval.
Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10
PK Parameter: CLss/F of Bictegravir Following Multiple-Dose Administration
CLss/F is defined as the apparent oral clearance following multiple-dose administration of the drug.
Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10
PK Parameter: AR_AUC of Bictegravir Following Multiple-Dose Administration
Accumulation ratio of AUC (AR_AUC) = AUCtau on Day 10 / AUC0-24 on Day 1. Percentage of accumulation ratio has been reported.
Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 and 10
PK Parameter: AR_Cmax of Bictegravir Following Multiple-Dose Administration
Accumulation ratio of Cmax (AR_Cmax) = Cmax on Day 10 / Cmax on Day 1. Percentage of accumulation ratio has been reported.
Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 and 10
PK/Pharmacodynamic (PD) Analysis: Pearson Correlation Between AUCtau of Bictegravir and DAVG11 in Plasma HIV-1 RNA
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). DAVG11 was defined as the time-weighted average between the first postbaseline value through the last available on-treatment (ie, the last dose date + 1) value up to Day 11 minus the baseline value in plasma HIV-1 RNA (log10 copies/mL).
Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10
Participants were enrolled at study sites in United States. The first participant was screened on 24 October 2014. The last study visit occurred on 29 January 2015.
| Milestone | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg | Placebo |
|---|---|---|---|---|---|
| Started | 5 | 4 | 5 | 5 | 4 |
| Completed | 4 | 4 | 4 | 4 | 4 |
| Not completed | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Randomized but not treated | 1 | 0 | 1 | 1 | 0 |
DAVG11 was defined as the time-weighted average between the first postbaseline value through the last available on-treatment (ie, the last dose date + 1) value up to Day 11 minus the baseline value in plasma HIV-1 RNA (log10 copies/mL). All HIV-1 RNA data up to Day 11 were used for this analysis. DAVG11 was calculated using the trapezoidal rule and the area-under-the-curve concept.
| log10 copies/mL | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 4.26 ± 0.157 | 4.64 ± 0.498 | 4.42 ± 0.458 | 4.71 ± 1.040 | 4.50 ± 0.407 |
| Change at Day 11 | -0.92 ± 0.104 | -1.33 ± 0.174 | -1.37 ± 0.310 | -1.61 ± 0.256 | -0.01 ± 0.144 |
| percentage of participants | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg | Placebo |
|---|---|---|---|---|---|
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) | 75.0 | 25.0 | 50.0 | 50.0 | 25.0 |
A treatment-emergent graded laboratory abnormality was defined as an increase of at least 1 toxicity grade from predose assessment and occurring after the predose visit and on or before the date of the last dose of study drug plus 30 days. If the predose assessment was missing, then any abnormality of at least Grade 1 associated with the study drug was considered a treatment-emergent graded laboratory abnormality. The most severe graded abnormality from all tests was counted for each participant.
| percentage of participants | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg | Placebo |
|---|---|---|---|---|---|
| Percentage of Participants Who Experienced Graded Laboratory Abnormalities | 75.0 | 25.0 | 0 | 25.0 | 50.0 |
Maximum reduction from baseline was defined as the minimum of change from baseline in plasma HIV-1 RNA (i.e. smallest change in HIV-RNA from baseline).
| log10 copies/mL | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg | Placebo |
|---|---|---|---|---|---|
| Maximum Reduction From Baseline Through Day 17 in Plasma HIV-1 RNA | -1.52 ± 0.079 | -2.18 ± 0.241 | -2.31 ± 0.191 | -2.91 ± 0.526 | -0.12 ± 0.177 |
Viral Decay Slope = (log10 \[HIV-1 RNA on Day x\] - log10 \[HIV-1 RNA on Day 1\]) / (x-1), where x is the collection day of the last available on treatment HIV-1 RNA collected up to Day 7.
| log10 copies/mL | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg | Placebo |
|---|---|---|---|---|---|
| Viral Decay Slope in Plasma HIV-1 RNA | -0.184 ± 0.0134 | -0.252 ± 0.0277 | -0.272 ± 0.0580 | -0.315 ± 0.0413 | -0.011 ± 0.0200 |
| percentage of participants | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg | Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL | 0 | 0 | 25.0 | 50.0 | 0 |
Cmax is defined as the maximum concentration of drug.
| ng/mL | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg |
|---|---|---|---|---|
| Single-Dose | 493.3 ± 72.12 | 2565.0 ± 331.31 | 4957.5 ± 667.60 | 7367.5 ± 2293.90 |
| Multiple-Dose | 741.5 ± 134.65 | 3475.0 ± 712.67 | 6080.0 ± 1323.20 | 12235.0 ± 3040.98 |
Tmax is defined as the time (observed time point) of Cmax.
| hours | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg |
|---|---|---|---|---|
| Single-Dose | 1.00 (1.00 to 1.25) | 1.83 (1.33 to 2.50) | 1.75 (1.50 to 2.50) | 1.50 (1.25 to 1.75) |
| Multiple-Dose | 1.50 (0.75 to 3.00) | 1.25 (1.00 to 1.50) | 1.75 (1.25 to 2.50) | 2.74 (1.25 to 3.99) |
AUC0-24 is defined as the concentration of drug over time from time zero to time 24 hours.
| ng*hr/mL | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg |
|---|---|---|---|---|
| PK Parameter: AUC0-24 of Bictegravir Following Single-Dose Administration | 6262.2 ± 1432.17 | 31291.8 ± 3113.91 | 68476.5 ± 11667.41 | 94588.5 ± 27376.40 |
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
| ng*hr/mL | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg |
|---|---|---|---|---|
| PK Parameter: AUClast of Bictegravir Following Single-Dose Administration | 6295.5 ± 1496.59 | 31401.0 ± 3123.59 | 68485.6 ± 11649.37 | 94827.0 ± 27262.26 |
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
| ng*hr/mL | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg |
|---|---|---|---|---|
| PK Parameter: AUCtau of Bictegravir Following Multiple-Dose Administration | 9983.0 ± 2664.77 | 48950.3 ± 19592.41 | 87538.4 ± 28649.77 | 178901.7 ± 31865.15 |
t1/2 is defined as the estimate of the terminal elimination half-life of the drug.
| hours | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg |
|---|---|---|---|---|
| PK Parameter: t1/2 of Bictegravir Following Multiple-Dose Administration | 20.79 (17.15 to 23.80) | 15.86 (14.07 to 19.37) | 17.84 (15.50 to 20.51) | 20.88 (17.91 to 24.47) |
Ctau is defined as the observed drug concentration at the end of the dosing interval.
| ng/mL | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg |
|---|---|---|---|---|
| PK Parameter: Ctau of Bictegravir Following Multiple-Dose Administration | 225.3 ± 84.57 | 1052.3 ± 568.90 | 2053.0 ± 977.35 | 4520.0 ± 991.90 |
CLss/F is defined as the apparent oral clearance following multiple-dose administration of the drug.
| mL/hr | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg |
|---|---|---|---|---|
| PK Parameter: CLss/F of Bictegravir Following Multiple-Dose Administration | 523.8 ± 115.43 | 567.3 ± 196.72 | 621.9 ± 211.73 | 570.6 ± 87.57 |
Accumulation ratio of AUC (AR_AUC) = AUCtau on Day 10 / AUC0-24 on Day 1. Percentage of accumulation ratio has been reported.
| percentage of AR_AUC | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg |
|---|---|---|---|---|
| PK Parameter: AR_AUC of Bictegravir Following Multiple-Dose Administration | 160.2 ± 25.86 | 157.4 ± 59.76 | 125.3 ± 20.92 | 193.3 ± 22.44 |
Accumulation ratio of Cmax (AR_Cmax) = Cmax on Day 10 / Cmax on Day 1. Percentage of accumulation ratio has been reported.
| percentage of AR_Cmax | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg |
|---|---|---|---|---|
| PK Parameter: AR_Cmax of Bictegravir Following Multiple-Dose Administration | 149.8 ± 6.61 | 138.5 ± 37.40 | 122.0 ± 13.31 | 168.4 ± 16.15 |
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). DAVG11 was defined as the time-weighted average between the first postbaseline value through the last available on-treatment (ie, the last dose date + 1) value up to Day 11 minus the baseline value in plasma HIV-1 RNA (log10 copies/mL).
| correlation coefficient | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg |
|---|---|---|---|---|
| PK/Pharmacodynamic (PD) Analysis: Pearson Correlation Between AUCtau of Bictegravir and DAVG11 in Plasma HIV-1 RNA | -1.000 | 0.275 | -0.940 | 0.713 |
Collected over First dose date up to last dose date plus 30 days (Maximum: 40 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bictegravir 5 mg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Bictegravir 25 mg | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Bictegravir 50 mg | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Bictegravir 100 mg | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Placebo | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Event | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg | Placebo |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/4 | 0/4 | 0/4 | 1/4 | 0/4 |
| FatigueGeneral disorders | 0/4 | 0/4 | 1/4 | 0/4 | 0/4 |
| NasopharyngitisInfections and infestations | 0/4 | 0/4 | 0/4 | 0/4 | 1/4 |
| Upper respiratory tract infectionInfections and infestations | 1/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| Arthropod biteInjury, poisoning and procedural complications | 0/4 | 0/4 | 0/4 | 1/4 | 0/4 |
| Blood creatine phosphokinase increasedInvestigations | 1/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| HeadacheNervous system disorders | 1/4 | 1/4 | 0/4 | 1/4 | 1/4 |
| PapuleSkin and subcutaneous tissue disorders | 0/4 | 0/4 | 1/4 | 0/4 | 0/4 |
The Safety Analysis Set included participants who were randomized and received at least 1 dose of bictegravir or matched placebo.
| Age, Continuous(years) | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 29 ± 4.0 | 44 ± 16.5 | 34 ± 11.5 | 36 ± 11.2 | 24 ± 3.2 | 33 ± 11.6 |
| Sex: Female, Male(Participants) | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 1 | 0 | 0 | 1 |
| Male | 4 | 4 | 3 | 4 | 4 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 1 | 0 | 1 | 6 |
| Not Hispanic or Latino | 2 | 2 | 3 | 4 | 3 | 14 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Race — Black | 0 | 1 | 1 | 1 | 3 | 6 |
| Race — White | 4 | 2 | 3 | 3 | 1 | 13 |
| Race — Other | 0 | 1 | 0 | 0 | 0 | 1 |
| Human Immunodeficiency Virus, Type 1 Ribonucleic Acid (HIV-1 RNA)(log10 copies/mL) | Bictegravir 5 mg | Bictegravir 25 mg | Bictegravir 50 mg | Bictegravir 100 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 3.76 ± 1.020 | 4.64 ± 0.498 | 4.42 ± 0.458 | 4.71 ± 1.040 | 4.50 ± 0.407 | 4.40 ± 0.745 |
Ran from Oct 2014 to primary completion in Jan 2015, 2 months.
Results were first posted in Oct 2020, 5 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bictegravir